PhilSayre, Ph.D.

Areas of Specialty

Dr. Sayre serves as a consultant to Wiley Rein LLP. He has more than 28 years of experience in the environmental field, specializing in assessing risks of commercial nanomaterials and microbial biotechnology products under The Toxic Substances Control Act (TSCA). He has participated as a lead in national and international regulatory test guideline work for nanomaterials.

Prior to joining Wiley Rein, Dr. Sayre worked principally as a Senior Scientist and Associate Division Director for the for the U.S. Environmental Protection Agency (EPA)’s Risk Assessment Division. In this capacity, he was involved in the health and ecological assessments of over 160 nanomaterial submissions that have been submitted to EPA for commercialization under TSCA. Dr. Sayre also worked on identifying hazards associated with many biotechnology submissions under Section 5 of TSCA, and was a lead author of the EPA “Points to Consider” guidance which is followed by biotechnology submitters under TSCA. Other positions held at EPA included those in OSWER, the SAB, and ORD. Prior to coming to EPA, Dr. Sayre completed biotechnology and chemical ecotoxicity, exposure, and risk assessments under the National Environmental Policy Act (NEPA) at FDA.

Representative Experience

As a senior scientist at EPA, Dr. Sayre:

Was involved in the health and ecological assessments of over 160 nanomaterial submissions admitted to EPA for commercialization under TSCA.

Identified hazards associated with many biotechnology submissions under Section 5 of TSCA.

Was lead author of the EPA guidance to be followed by biotechnology submitters under TSCA.

SIGNAL Group (formerly McBee Strategic Consulting, LLC) is a wholly owned subsidiary of Wiley Rein. SIGNAL is a total solutions provider—advocacy, strategic communications, research, and digital media—for clients seeking to engage the federal government to achieve competitive advantage, influence public policy, establish new markets, and secure public capital.